KR100192622B1 - 페네타놀아민 화합물 - Google Patents

페네타놀아민 화합물 Download PDF

Info

Publication number
KR100192622B1
KR100192622B1 KR1019900016017A KR900016017A KR100192622B1 KR 100192622 B1 KR100192622 B1 KR 100192622B1 KR 1019900016017 A KR1019900016017 A KR 1019900016017A KR 900016017 A KR900016017 A KR 900016017A KR 100192622 B1 KR100192622 B1 KR 100192622B1
Authority
KR
South Korea
Prior art keywords
compound
hydroxy
disease
amino
phenylbutoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019900016017A
Other languages
English (en)
Korean (ko)
Other versions
KR910007867A (ko
Inventor
에반스 브라이언
Original Assignee
그레이엄 브레레톤, 레슬리 에드워즈
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898922795A external-priority patent/GB8922795D0/en
Priority claimed from GB909012472A external-priority patent/GB9012472D0/en
Application filed by 그레이엄 브레레톤, 레슬리 에드워즈, 글락소 그룹 리미티드 filed Critical 그레이엄 브레레톤, 레슬리 에드워즈
Publication of KR910007867A publication Critical patent/KR910007867A/ko
Application granted granted Critical
Publication of KR100192622B1 publication Critical patent/KR100192622B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C07C215/32—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton containing hydroxy groups and carbon atoms of two six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019900016017A 1989-10-10 1990-10-10 페네타놀아민 화합물 Expired - Fee Related KR100192622B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB89227953 1989-10-10
GB898922795A GB8922795D0 (en) 1989-10-10 1989-10-10 Chemical compounds
GB90124728 1990-06-05
GB909012472A GB9012472D0 (en) 1990-06-05 1990-06-05 Chemical compounds

Publications (2)

Publication Number Publication Date
KR910007867A KR910007867A (ko) 1991-05-30
KR100192622B1 true KR100192622B1 (ko) 1999-06-15

Family

ID=26296026

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900016017A Expired - Fee Related KR100192622B1 (ko) 1989-10-10 1990-10-10 페네타놀아민 화합물

Country Status (10)

Country Link
EP (1) EP0422889A3 (enExample)
JP (1) JPH03133946A (enExample)
KR (1) KR100192622B1 (enExample)
AU (1) AU629989B2 (enExample)
CA (1) CA2027262A1 (enExample)
IE (1) IE903614A1 (enExample)
IL (1) IL95936A (enExample)
NZ (1) NZ235605A (enExample)
PT (1) PT95542B (enExample)
TW (1) TW209832B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
GB9215274D0 (en) * 1992-07-17 1992-09-02 Scras Derivatives of(phenylethyl-beta-ol)amine
ES2065269B1 (es) * 1993-05-11 1995-10-01 S A L V A T Lab Sa 6-(4-(fenilbutoxi) hexilaminometil-4-hidroxi-a1,a3-bencenodimetanol. procedimiento para la obtencion del mismo y nuevos intermedios utilizados en su preparacion.
ES2121621T3 (es) * 1993-12-10 1998-12-01 Novartis Ag Derivados de acido n,n'-bis(2-hidroxibencil)etilendiamino-n,n'-diacetico como agentes quelantes.
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
ZA994264B (en) 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
US7232837B2 (en) 1999-06-29 2007-06-19 Mcneil-Ppc, Inc. Stereoisomers with high affinity for adrenergic receptors
GB0014546D0 (en) * 2000-06-14 2000-08-09 Glaxo Group Ltd A novel process
GB0105560D0 (en) * 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
WO2007045857A1 (en) * 2005-10-17 2007-04-26 Generics (Uk) Limited Novel process
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
WO2009154557A1 (en) 2008-06-18 2009-12-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
WO2016142582A1 (en) 2015-03-11 2016-09-15 Fermion Oy Process for the preparation of crystalline salmeterol and its xinafoate salt

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8310477D0 (en) * 1983-04-18 1983-05-25 Glaxo Group Ltd Chemical compounds
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
DE3806321A1 (de) * 1988-02-27 1989-09-07 Boehringer Mannheim Gmbh Neue trisubstituierte amine, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten

Also Published As

Publication number Publication date
TW209832B (enExample) 1993-07-21
EP0422889A3 (en) 1991-08-28
PT95542A (pt) 1991-08-14
NZ235605A (en) 1992-12-23
IE903614A1 (en) 1991-04-24
PT95542B (pt) 1999-09-30
CA2027262A1 (en) 1991-04-11
IL95936A (en) 1996-01-19
IL95936A0 (en) 1991-07-18
JPH03133946A (ja) 1991-06-07
AU629989B2 (en) 1992-10-15
AU6390190A (en) 1991-04-18
EP0422889A2 (en) 1991-04-17
KR910007867A (ko) 1991-05-30

Similar Documents

Publication Publication Date Title
KR100192622B1 (ko) 페네타놀아민 화합물
EP0162576B1 (en) Ethanolamine compounds
KR20030093279A (ko) 2-아미노-프로판올 유도체
CH661497A5 (fr) Composes de phenethanolamine.
JPH01139565A (ja) フェネタノールアミン誘導体
EP1439164B1 (en) Novel phenylethanolamine compounds having beta2-acceptor excitatory function and their preparation method
KR870001927B1 (ko) 피리딜 화합물의 제조방법
JP2719947B2 (ja) 心臟血管系に対し活性な化合物
FI120400B (fi) Antineurodegeneratiivisesti vaikuttavat 10-aminoalifatyylidibents(b,f )oksepiinit
KR840001552B1 (ko) 시클로헥센 유도체의 제조방법
JPS61249951A (ja) シクロペンチルエ−テル類、それらの製法および医薬組成物
EP1412332A1 (en) Quinoline derivatives and use thereof as antitumor agents
AU643099B2 (en) Pharmaceutically active phenylalkylamino-alkyl compounds
US20030065186A1 (en) Novel 4-diphenylethyl piperidine derivatives
KR20010022147A (ko) 아미노시클로알칸 화합물
AU635424B2 (en) Dichloroaniline compound
US5539128A (en) Processes and intermediates for preparing cis(+)3-[4,6-dihydroxy chroman-3-ylmethyl]-4-methoxyaniline
JP2772650B2 (ja) 新規化合物およびその医薬的用途
HUT53615A (en) Process for producing thioformamide derivataives and pharmaceutical compositions comprising same
JPH10212232A (ja) ジアリールアルカン誘導体を有効成分とする膵炎治療剤又は予防剤
CA2075485A1 (en) Thioformamide derivatives
HK1064664B (en) Novel phenylethanolamine compounds having beta2-acceptor excitatory function and their preparation method
EP0120304A2 (en) Substituted 4,10-dihydro-10-oxothieno benzoxepins and intermediates thereof, a process for their preparation and their use as medicaments
WO1999054278A1 (en) 1-(2-ALKOXY-5-CARBOXYPHENYL)-α,β-UNSATURATED KETONES, THEIR PREPARATION AND APPLICATION IN THERAPEUTICS
JPS60248650A (ja) エタノ−ルアミン化合物

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20020123

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20030130

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20030130

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000